论文部分内容阅读
目的:对比胰激肽释放酶联合硫酸镁治疗前、后子痫前期患者血液、尿液及胎盘中激肽释放酶表达差异,探讨胰激肽释放酶治疗子痫前期的临床疗效。方法:采用胰激肽释放酶+硫酸镁(研究组)和硫酸镁(对照组)分别治疗子痫前期患者20例,采用逆转录-聚合酶链反应(RT-PCR)及酶底物S2266分别检测治疗前、后对照组和研究组血液、胎盘中激肽释放酶基因表达及尿液中激肽释放酶表达活性的差异;同时对比组内及组间临床指标的差异。结果:研究组治疗后血液、尿液激肽释放酶表达增强(P<0.05);对照组治疗后血液、尿液激肽释放酶表达水平无明显改变(P>0.05);两组治疗后胎盘激肽释放酶基因表达组间差异有统计学意义(P<0.05)。两组治疗后平均动脉压、24 h尿蛋白均有下降(P<0.05),但研究组下降程度较之对照组更明显(P<0.05)。两组治疗后母儿结局,新生儿胎龄及出生体重研究组均大于对照组(P<0.05)。结论:胰激肽释放酶联合硫酸镁治疗能增强子痫前期患者体内激肽释放酶基因的表达,并能有效改善子痫前期患者部分临床指标,较之单一使用硫酸镁更能有效治疗子痫前期。
OBJECTIVE: To compare the expression of kallikrein in blood, urine and placenta of patients with preeclampsia and pre-eclampsia treated with kallikrein and magnesium sulfate, and to explore the clinical efficacy of kallikrein in the treatment of preeclampsia. Methods: Twenty patients with preeclampsia were treated with pancreatic kallikrein + magnesium sulfate (study group) and magnesium sulfate (control group), respectively. RT-PCR and S2266 The changes of kallikrein gene expression in the blood and placenta and the expression of kallikrein in urine of the control group and the study group before and after treatment were compared, and the differences of clinical indexes between the two groups were also compared. Results: The levels of blood and urine kallikrein in the study group were significantly increased (P <0.05). The levels of blood and urine kallikrein in the control group were not significantly changed after treatment (P> 0.05) There was a significant difference between the kallikrein gene expression groups (P <0.05). Mean arterial pressure and 24-hour urine protein in both groups decreased after treatment (P <0.05), but the decrease in study group was more significant than that in control group (P <0.05). Maternal outcome, neonatal gestational age and birth weight in the two groups were significantly higher than those in the control group (P <0.05). Conclusions: Kallikrein combined with magnesium sulfate can enhance the expression of kallikrein gene in preeclampsia patients, and can effectively improve some clinical indexes in patients with preeclampsia, which is more effective than single magnesium sulfate in the treatment of eclampsia Early.